Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...

The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates Medtronic is the first and only ...

Please provide your email address to receive an email when new articles are posted on . Medtronic announced its cardiac lead received an expanded indication from the FDA for left bundle branch area ...

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

What Is the Heart Conduction System? The heart conduction system is made up of cells, nodes, and signals that help your heart to beat. In fact, the cardiac conduction system is responsible for our ...

Researchers have produced the most detailed and comprehensive human Heart Cell Atlas to date, including the specialized tissue of the cardiac conduction system -- where the heartbeat originates. In a ...

A Baylor College of Medicine multi-institution, collaborative study to determine the effectiveness and safety of commonly used pacing treatments for cardiac resynchronization therapy in people with ...

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...